Renal Cell Carcinoma: Interpreting Cross-Trial Comparisons

In this segment, Dr. Elizabeth Plimack leads a discussion with Dr. Sundhar Ramalingam and Dr. Yasser Ged on the challenges of comparing first-line treatment regimens in renal cell carcinoma across different clinical trials. The panel emphasizes that while multiple IO plus TKI and IO plus IO combinations have demonstrated meaningful survival benefits, direct comparisons between studies can be misleading due to differences in trial design, patient populations, and endpoints. Dr. Ramalingam and Dr. Ged highlight the importance of evaluating each trial within its own context, rather than drawing conclusions based on indirect comparisons. The discussion also underscores the role of clinical judgment in integrating available evidence with patient-specific factors. This segment reinforces the need for a thoughtful and nuanced approach when interpreting data to guide first-line treatment selection in renal cell carcinoma.